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Abstract: Alcohol exposure during pregnancy constitutes one of the leading preventable
causes of birth defects, mental retardation and neurodevelopmental disorders in exposed
children. According to the 2016 National Survey on Drug Use and Health, alcohol was
the second most prevalent substance (8.3%) after tobacco (10%), being this alcohol
prevalence higher among 26-44 years old pregnant women than in the 18-25 years old
group (9.1 vs 6.5%) (Center for Behavioral Health Statistics and Quality, 2017). The
ethanol marker ethyl glucuronide (EtG) has proven to be a specific long-term marker of
ethanol in-utero exposure in meconium; however, currently there are scarce or no data
about EtG and ethyl sulfate (EtS) in umbilical cord and placenta. These tissues are
alternative matrices to meconium that offer critical advantages; as they are always
available at birth, their collection is noninvasive and easy, and they are considered waste
products. We developed a method for the determination of EtG and EtS in 0.1 g of
umbilical cord and placenta, achieving a limit of quantification of 5 ng/g in umbilical
cord and 10 ng/g in placenta. Tissues were homogenized in methanol and the analytes of
interest were extracted using weak anion exchange solid phase extraction and analyzed
by liquid chromatography tandem mass spectrometry (LC-MSMS), in negative mode,
monitoring 2 transitions per analyte. The methods were applied to 59 authentic umbilical
cord and placenta samples from newborns whose meconium samples were positive for
EtG (EtG > 5 ng/g). EtG and/or EtS were detected in 25 umbilical cord samples with
ranges of 4.4-528.5 ng/g and 4.3-39 ng/g, respectively, and in 8 placenta samples with
ranges of 26.5-266.5 and 11-24.3 ng/g, respectively. EtG and EtS showed a homogenous
distribution throughout umbilical cord tissue (n=5). To date, this is the first method to
investigate both minor metabolites of ethanol in term umbilical cord and placenta

samples for prenatal ethanol exposure.
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1. Introduction
Although drinking alcohol while pregnant has long been regarded as harmful to a
developing fetus, according to the Centers for Disease Control and Prevention (CDC),
about 10% of pregnant women in US drink alcohol, while a third of that population
participates in binge drinking (Tan et al., 2015). Alcohol consumption during pregnancy
may happen due to preconceived notions among the population that a minor amount of
alcohol during the course of pregnancy can be harmless. However, there is no amount of
ethanol deemed safe for consumption during pregnancy (CDC, 2004), which ideally
should lead to abstinence from alcohol in this population.
Alcohol exposure places a fetus at risk of developing conditions such as fetal
alcohol syndrome and other alcohol related neurodevelopmental disorders which
manifest as cognitive impairments (Denkins et al., 2000). Also, this exposure may result
in a range of birth defects and subsequent neurodevelopmental problems, including
distinctive craniofacial dysmorphology, compromised growth, and cognitive and social
impairments (Vaiano et al., 2016). According to a study by Burd, Blair, & Dropps,
(2012), due to the reduced fetal metabolic capacity and the reabsorption of ethanol from
contaminated amniotic fluid, fetal blood alcohol concentration (BAC) levels can reach
those of the mother within 1-2 hours of maternal ingestion. Thus, the effects experienced
at these blood alcohol levels can affect the fetus with the same intensity as a grown adult,
and because the fetus is in a vulnerable stage of development, such effects have been seen
to hinder and negatively affect this crucial developmental period. As a result, the
consumption of alcohol over the duration of a pregnancy is seen as an act that directly
affects and compromises the well-being of a developing fetus.
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While the possibility of birth defects and cognitive impairments is in and of itself
detrimental enough, the risk of more life-threatening conditions can manifest from
alcohol use during pregnancy. While the connection is still unclear, it has been seen that
there is a possible link between the use of alcohol during pregnancy and an increased risk
of stillbirth, miscarriage and sudden infant death syndrome (SIDS) (Bailey & Sokol,
2011). Though it is true that causality has not been established, it is wise to err on the side
of safety considering the possible risks. In such cases, determining the cause of the
above-mentioned outcomes can be imperative in deciding to take medical and/or legal
interventions for the act of drinking and its consequences. Thus, it is crucial to be able to
objectively determine whether or not there was fetal ethanol exposure and if it could have
possibly contributed to such an outcome.
Several matrices and biomarkers have been investigated to determine fetal
exposure to ethanol, in combination with the self-reported values of alcohol consumption
over the duration of pregnancy. The use of biomarkers is superior to that of self-reported
questionnaires alone, due to their lack of sensitivity and reliability (Vaiano et al., 2016).
Various analytes studied include the traditional ethanol biomarkers such as the fatty acid
ethyl esters (FAEEs), serum carbohydrate deficient aminotransferase and the
transaminases aspartate transaminase (AST) and alanine transaminase (ALT), in addition
to minor ethanol metabolites ethyl glucuronide (EtG) and ethyl sulfate (EtS). The
traditional biomarkers lack the sensitivity and specificity that EtG and EtS afford, thus
making them less desirable (Høiseth, Morini, Polettini, Christophersen, & Mørland,
2009). The traditional biomarkers are affected by factors outside of ethanol consumption
that compromise the specificity of the data obtained from their analysis. If the origin of
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elevated concentration of these biomarkers may be ambiguous, inconclusive data is
obtained, and therefore, the goal of identifying in-utero exposure to ethanol is not
fulfilled. Additionally, fatty acid ethyl esters have been seen to lack stability in biological
samples as meconium (Himes et al. 2015), thus further compromising the data obtained.
EtG and EtS, which are minor metabolites of ethanol, have demonstrated to be
specific and long-term biomarkers of ethanol use in different types of biological samples,
such as urine, hair and meconium (Politi, Morini, Leone, & Polettini, 2006). Meconium,
the first feces of a newborn, has been used to detect fetal exposure to ethanol during
pregnancy because it is an accumulation of the waste products produced during the
second and mainly the third trimesters, therefore it may account for the exposure in that
period of time. Several papers have established EtG cutoffs to detect ethanol exposure
during pregnancy, based upon evaluation of newborns that were not exposed to ethanol,
and the extent of agreement with FAEE concentrations and/or maternal self-reports
(Pichini et al., 2012; Bakdash et al., 2010; Himes et al., 2015; Goecke et al., 2014; Morini
et al., 2010a). These cutoffs are necessary because baseline EtG and EtS concentrations
in meconium may be present due to ethanol exposure from sources other than drinking
alcoholic beverages (Morini et al., 2010a; Bakdash et al., 2010). Meconium, however,
can be difficult to collect, and its limited sample size can sometimes present a problem
when it comes to confirmatory testing. In cases of stress on the fetus, meconium can be
passed before birth rendering it inaccessible and thus unusable for analysis (Montgomery
et al., 2005).
As an alternative matrix for detection of in-utero exposure to ethanol, umbilical
cord has seldom been investigated. Only one study conducted in 2012 determined a
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method for the detection of two ethanol biomarkers, 1-palmitoyl-2-oleoyl-sn-glycero-3phosphoethanol (POPE) and EtG, but did not look at EtS (Jones, Jones, Plate, & Lewis,
2012). The inclusion of EtS can provide greater evidence of ethanol consumption as
opposed to EtG alone, as they are both direct metabolites of ethanol. Because the cord
tissue provides the connection through which the fetus is nourished, it is reasonable that
whatever compounds are detected in this tissue will have been passed to the fetus as well.
The umbilical cord contains 3 vessels – 2 arteries and 1 vein – which help to circulate
nutrients and oxygen from the mother to the growing fetus (Bosselmann & Mielke,
2015). These vessels feed into the hepatic portal vein and inferior vena cava of the fetus
(Ellis, 2005), sending these nutrients directly into the bloodstream for circulation and
partially bypassing first pass metabolism. Obtaining umbilical cord tissue is not invasive
nor does it require extra work, as the umbilical cord is always severed after birth, making
it a convenient sample for analysis. Because the cord tissue is available upon birth, there
is also no wait time, as is the case with meconium (Palmer, Wood, & Krasowski, 2017),
and analytical data can be provided sooner to determine the necessary course of action.
An additional matrix for investigation is the placenta, the organ connecting the
fetus to the uterine wall of the mother and allowing nutrient and oxygen exchange
between mother and baby (Burton & Jauniaux, 2015). Amongst its many functions,
because the placenta is responsible for the transport of nutrients to the fetus, it is
hypothesized that substances present in the placenta will be present in the fetus as well.
Previous research regarding EtG and EtS in placenta has been conducted, with successful
results in the detection of both analytes. Morini et al. (2011) presented a fully validated
method applied to authentic placenta samples and paired fetal tissues, while Swortwood
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et al. (2018) presented a fully validated method applied to authentic placenta samples and
paired fetal liver. Both articles investigated samples obtained from pregnancies
voluntarily terminated around 8-20 weeks of gestation, indicating ethanol exposure in the
first and early second trimester.
The goal of the present study was to develop and validate analytical methods for
the determination of EtG and EtS in umbilical cord and placenta samples. These methods
were applied to authentic term umbilical cord and placental samples from newborns
whose paired meconium samples tested positive for EtG. Such methods and data will
allow for the determination and will improve the interpretation of ethanol exposure
during pregnancy, to aid individuals in the clinical and forensic scientific fields in
understanding the newborns’ outcomes and the medical, legal and social consequences of
this exposure. By finding appropriate biomarkers and matrices and utilizing them
properly in order to detect in-utero alcohol exposure as early as possible, the risk of
developmental damage and long-term impairments can be minimized, therefore
improving the livelihood of the affected children.

2. Materials and methods
2.1. Reagents and materials
EtG and EtS were purchased from Cerilliant (Round Rock, TX, USA), as well as
the deuterated analogs, EtG-d5 and EtS-d5. Reagent grade formic acid, and liquid
chromatography mass spectrometry (LCMS) grade acetonitrile, isopropanol, formic acid
and methanol were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
Reagent grade dichloromethane, ammonium hydroxide and methanol were purchased
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from Pharmco-Aaper (Brookfield, CT, USA). Strata-X-AW 33 µm polymeric weak anion
exchange cartridges of 3 mL/200 mg were purchased from Phenomenex (Torrance, CA,
USA). Sarstedt Inc 10 mL sc tubes 16x100 mm and 350 µL fused insert vials were
acquired from Thermo Fisher Scientific. Filter vials nano/Filter vial® 0.2 µm PVDF with
red non-slit cap were from Thomson Instrument Company (Oceanside, CA, USA).
2.2. Method optimization
In order to obtain the most efficient method while maximizing sensitivity and
specificity, mass spectrometry, chromatography, homogenization and extraction methods
were optimized. Mass spectrometry for EtG and EtS was first optimized by determining
which transitions to monitor by direct injection (no column) of 2 µL of individual
solutions at 0.1 µg/mL. Using the molecular weight and the electrospray ion source in
negative mode, the precursor ion was obtained and a list of fragment ions with various
intensities were compiled. The two fragments with the highest intensities were used to
produce the target transitions. The parameters (entry and exit quadrupole voltages and
collision energies) to provide the greatest intensity for these transitions were also
optimized and recorded for the methods to be developed. Further optimization was
performed by varying the probe voltage and flow rates of nebulizing, drying and
desolvation line gases to obtain results with the greatest intensities.
Chromatographic optimization was performed by utilizing methods proposed by
other authors (Pragst et al., 2010; Himes, Concheiro, Scheidweiler, & Huestis, 2014;
Vaiano et al., 2016) with slight modifications to mobile phase compositions,
chromatographic columns, gradients and flow rates. The goal was to produce a gradient
in which both analytes, EtG and EtS, were retained for enough time while providing
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adequate baseline resolution of peaks. Peak shifting was minimized by including a reequilibration period after the gradient.
Mechanical homogenization (tissue blender) of the umbilical cord and placenta
tissue was optimized by utilizing various solvents including methanol and water with
additives to prevent agglutination of the homogenate, such as formic acid and ammonium
hydroxide.
Multiple extraction methods for umbilical cord and placenta matrices were
investigated and modified to determine the most efficient and successful method (Himes
et al., 2014; Sanvisens et al., 2016). Extraction of umbilical cord and placenta samples
was complicated by the fact that EtG and EtS appear to be governed by different
mechanisms, making their retention and elution complex. Various cartridge chemistries
were applied including strong and weak anion exchange, carbon packing and
aminopropyl cartridges. Because of the different properties of EtG and EtS, various
loading conditions and elution as a 1 or 2 step process were also tested.
2.3. Preparation of calibration and quality control samples
Calibrators were prepared at 5, 25, 50, 100 and 500 ng/g of umbilical cord, and
10, 25, 50, 100 and 500 ng/g of placenta using working solutions containing both EtG
and EtS at 0.01, 0.1 and 1 µg/mL each, prepared from serial dilutions of 1 mg/mL stock
solutions of EtG and EtS. Internal standard (IStd) EtG-d5 and EtS-d5 mixture at 1 µg/mL
was prepared in methanol. All solutions were stored in amber vials at -20°C.
2.4. Sample homogenization
Umbilical cord and placenta samples were cut into ~ 2-mm sized portions and
weighed to 100 mg (± 5 mg) in a 10-mL Sarsted tubes. Samples were spiked with 25 µL
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of the IStd working solution at 1 µg/mL. Scissors and tweezers used for cutting the
samples were rinsed with water and methanol and dried before moving onto samples
from different donors to avoid cross contamination. Two mL of methanol were added and
samples were vortexed and homogenized using a tissue blender Omni International
Mixer/Homogenizer (Kennesaw, GA, USA) until there were no longer any visible chunks
of the tissues. Trapped chunks of the tissue were manually removed using a wooden
toothpick and the blender blades were rinsed between samples by immersing the blades
in a 50-mL falcon tube filled halfway with water and turning on the power, then wiping
down the instrument. The same process was then repeated using a falcon tube filled with
methanol and wiped down before moving onto the next sample. Homogenates were then
centrifuged at 7,830 rpm at 4˚C for 10 minutes using an Eppendorf 5430 centrifuge
(Hauppauge, NY, USA). The supernatant was collected (~ 2 mL) and submitted to solid
phase extraction.
2.5. Solid Phase Extraction (SPE)
Extraction of EtG and EtS in umbilical cord and placenta tissues was performed
using Strata-X-AW weak anion exchange 3 mL/200 mg cartridges conditioned with 2 mL
of methanol, followed by 2 mL of 1% formic acid in water. The supernatant from the
sample homogenates were loaded into the cartridge and allowed to flow via gravity.
Cartridges were washed with 2 mL of water and then dried under vacuum (~ 15-20 Hg)
for 15 minutes. EtG samples were eluted first via gravity with 2 mL of 5% formic acid in
methanol and light vacuum was applied to collect the entire sample. Cartridges were
washed with 2 mL of methanol and then briefly dried using vacuum. EtS samples were
then eluted via gravity using 5% ammonium hydroxide in acetonitrile and light vacuum
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was applied once more to collect the entire sample. Fresh elution solvents were prepared
prior to each extraction to maintain the integrity of its properties.
Both eluates were evaporated under a stream of N2 gas in a Biotage TurboVap LV
(Charlotte, NC, USA) at 50˚C. Umbilical extracts were reconstituted in 100 µL of 0.1%
formic acid in water, vortexed for a minimum of 15 seconds, centrifuged at 7,830 rpm at
4˚C for 10 minutes using an Eppendorf 5430 centrifuge, and 60 µL were transferred to
the injection vials. In the case of the placenta extracts, samples eluted using 5% formic
acid in methanol (EtG eluate) contained blood and particles that could not be removed by
centrifugation. Because of that, these extracts were reconstituted using 200 µL and
filtered using nano filter vials from Thomson Instrument Company. All analyses were
carried out injecting 20 µL of sample.
2.6. Instrumentation
Samples were analyzed on a liquid chromatography tandem mass spectrometry
LC-MS 8050 instrument from Shimadzu (Columbia, MD, USA). The Nexera HPLC
system consisted of a binary LC-20AD XR pump, online degassing unit DGU-20A 3R,
cooled autosampler SIL-20A XR and column oven CTO-20AC. The chromatographic
column employed was a Kinetex polar C18 column (2.1 mm x 100 mm, 2.6 µm particle
size, 100 Å pore size) with a KrudKatcher ULTRA HPLC In-Line Filter guard column
(0.5 µm x 0.004 in) from Phenomenex (Torrence, CA, USA). Mobile phase A consisted
of 0.1% formic acid in ultra-high purity (UHP) water, and mobile phase B consisted of
0.1% formic acid in LC-MS grade acetonitrile. The column oven was operated at 30˚C
and the flow rate was set to 0.3 mL/min. The following gradient adapted from a
previously published method in meconium (Himes et al., 2014) was utilized for analysis:
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at time 0 minutes gradient is increased from 0% B to 95% B until 3.6 minutes and held at
95% until 7.5 minutes. From 7.5 minutes to 7.6 minutes, the gradient is deceased from
95% B to 0% B and held at 0% until 11 minutes.
The mass spectrometer employed was a triple quadrupole mass spectrometer
using an electrospray ionization source operating in negative mode (ESI-). Both methods
employed the following source parameters: ionization voltage at -3 kV, nebulizing gas
flow at 2 L/min, heating gas flow at 15 L/min, drying gas flow at 5 L/min, interface
temperature at 300˚C, heating block temperature at 400˚C and desolvation line
temperature at 250˚C. The compound transitions were monitored using the multiple
reaction monitoring (MRM) mode. The two transitions for each compound and their
deuterated analogs are listed in table 1.
Table 1: MRM transitions monitored and energy conditions for EtG, EtS, and their
deuterated analogs.
Compound Precursor Transition Q1
ion
1
EtG
220.8
75.2
11
EtS
125.1
97.05
13
EtG-d5
226
75.1
15
EtS-d5
130
98.05
13

CE

Q2

15
20
17
18

14
17
13
18

Transition
2
84.9
80
84.9
79.95

Q1

CE

Q2

15
13
16
13

17
31
16
32

21
14
23
14

2.7. Method validation
Guidelines for method validation were obtained from procedures presented by the
Scientific Working Group for Forensic Toxicology (Scientific Working Group for
Forensic Toxicology (SWGTOX), 2013). Parameters under investigation were linearity,
limit of detection (LOD), limit of quantification (LOQ), intra- and inter-day accuracy and
precision using quality control (QC) samples, endogenous and exogenous interferences,
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carryover, autosampler stability, extraction efficiency, matrix effect and overall process
efficiency.
Determination of linearity for the calibration model was investigated over 5
different days using at least 5 non-zero calibrators. Each calibration curve was prepared
using a different donor source of either umbilical cord or placenta. The calibration model
was evaluated using a least-squares residual model incorporating different weighting
factors (non-weighted, 1/x and 1/x2) to produce the simplest yet most accurate calibration
model. Linearity was considered acceptable if the individual residuals were within a ±
20% range of the indicated concentration, and the coefficient of determination was ≥
0.99. The LOD and LOQ were chosen to be at the same concentration as the lowest nonzero calibrator, and were examined in triplicate over 3 different days using a different
donor source for each day. The accuracy and precision of the LOD/LOQ samples were
required to be within ± 20% of the established concentration in order to pass.
Inter and intra-day precision and accuracy were assessed using QC samples at 15
ng/g (low QC) and 300 ng/g (high QC). Accuracy and precision were evaluated with
triplicate samples at each concentration over 5 different days. Accuracy was determined
by measuring the bias via percent error of QC samples, and was determined to be
acceptable if results were within a ± 20% range of the indicated concentration. Precision
was assessed by measuring the coefficient of variation (CV) between the samples and
was considered acceptable if below 20%. The formulas utilized to study these parameters
are summarized in Table 2.
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Table 2: Formulas for Validation Parameters.
Parameter Studied
Accuracy
Bias
Imprecision (Coefficient of Variation)

Formula Utilized
(Mean Concentration/Nominal
Concentration) * 100%
[(Mean Concentration-Nominal
Concentration)/Nominal Concentration)]
* 100%
(Standard Deviation/Mean Concentration)
* 100%

To determine carryover, blank samples from the calibration model, spiked only
with IStd, were reinjected directly after the highest calibrator, on 5 different days.
Carryover was considered absent if the concentration calculated from the signal at the
point of interest was below that of the LOD. Autosampler stability was evaluated by
reinjecting 6 QC samples (3 low and 3 high) after 48 hours in the autosampler at 10˚C.
Samples were considered stable in the autosampler if the concentrations calculated were
within ± 20% of their initial concentration.
Extraction efficiency (EE), matrix effect (ME) and process efficiency (PE) were
determined via a series of neats and samples fortified before and after extractions at high
QC (HQC) and low QC (LQC) levels. To evaluate, a set of 6 neats was produced by
fortifying empty Sarsted tubes with the correct volumes of working solutions and IStd
necessary to obtain either 15 ng/g or 300 ng/g. A second set of samples was produced by
fortifying 6 blank umbilical cord or placenta samples from different donors at the LQC
level, and 6 at the HQC level, and extracting via SPE. These were the “before extraction”
samples. A third set of samples was produced by extracting 12 blank umbilical cord or
placenta samples from different donors without fortification. After SPE, the samples were
fortified in the same manner as the neats and “before extraction” samples – 6 at the LQC
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level and 6 at the HQC level. This set was the “after extraction” samples. Samples were
evaporated to dryness following the same protocol discussed previously and reconstituted
in either 100 µL or 200 µL of 0.1% formic acid in water depending on the procedure
protocol. Samples from the neat set and the “after extraction” set were compared to
evaluate ME. EE was examined by comparing samples from the “before extraction” and
“after extraction” set, and overall PE was evaluated by comparing the neat set with the
“before extraction” set. The formulas utilized for studying ME, EE and PE are
summarized in Table 3, using mean peak areas for calculations.
Table 3: Formulas for matrix effect, extraction efficiency and process efficiency.
Parameter Studied
Matrix Effect
Extraction Efficiency
Process Efficiency

Formula Utilized
[(MeanAfter-MeanNeat)/ MeanNeat] * 100%
(MeanBefore/MeanAfter) * 100%
(MeanBefore/MeanNeat) * 100%

Homogenate stability was also tested using one LQC and one HQC sample. Cord
samples were fortified with appropriate volumes of analyte and IStd working solutions
and homogenized following the previously mentioned procedure. After centrifugation,
sample homogenates were collected and placed in the refrigerator at 4˚C overnight and
extracted the following day. These samples were compared to QC samples that were
homogenized, extracted and analyzed in the same day to determine sample stability. This
stability component was added in order to assess the ability to split sample preparation
and sample extraction into 2 days for the analysis of authentic samples in order to
maximize efficiency.
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Endogenous and exogenous interferences were assessed to determine method
specificity. Endogenous interferences were determined by extracting blank umbilical cord
or placenta samples and analyzing with the addition of IStd. Using a total of 10 different
blank umbilical cord sources and 7 different blank placenta sources, endogenous
interferences were assessed by reviewing the blank samples. Exogenous interferences
were determined by analysis of neat samples containing common drugs of abuse,
including cocaine, cannabis, various amphetamines and opioids, at a concentration equal
to that of the highest calibrator (500 ng/g). Interferences were considered absent if the
concentration calculated from the signal at the points of interest was below that of the
LOD.
2.8. Identification criteria
In order to confirm the presence and identity of substances in a sample,
identification criteria must be adhered to. In order to confirm the success of the sample
extraction and overall method, the IStd must be present in all of the samples that it was
added to. Moving forward, the substance detected must be within a 0.2-minute range of
the average retention time of the substance in the calibrators. Two transitions (quantifier
and qualifier, indicated in table 1) must also be detected for each compound, and must be
present in a specific ratio to one another. This ratio of the qualifier to quantifier
transitions must be within 20% of the average determined for the calibrators. Only after
all of these standards have been met can a compound be confirmed present.
2.9. Authentic umbilical cord and placenta specimens
Human blank umbilical cord samples were purchased from Lee BioSolutions
(Maryland Heights, MO, USA), and were stored at -20°C. Authentic umbilical cord and
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placenta samples (blank and positive cases) were collected during a study to investigate
alternative matrices to detect in-utero drug exposure (Concheiro et al., 2017). Umbilical
cord and placenta samples were collected at delivery in polypropylene containers and
stored at -20°C until analysis, and meconium samples were collected from newborn
diapers up to 3 days after delivery in polypropylene containers and also stored at -20°C
until analysis. The participants were pregnant women who delivered at the University
Hospitals of Santiago de Compostela and Vigo, Spain, from January 2012 to December
2015. The participants were informed about the study both in writing and orally before
the delivery, and they gave written consent. The subjects were not paid for their
participation. The study was approved by the Ethics Committee of the University of
Santiago de Compostela, Spain.
EtG meconium analysis was performed at the Toxicology Service of the
University of Santiago de Compostela (Spain) following their routine analysis procedure.
Briefly, 0.5 g of meconium were ultrasonicated in acetonitrile, and the supernatant was
submitted to aminopropyl solid phase extraction cartridges (Sep-Pack NH2 cartridges,
Waters, Milfrod, MA). The analysis was performed by LC-MSMS (Quattro MicroTM API
ESCI triple quadrupole, Waters), in ESI-, using 2 transitions per compound. The
chromatographic separation was performed using a Hypercarb 100x2.1 mm column
(Thermo Fisher Scientific). EtG linearity in meconium was from 5 to 500 ng/g.
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3. Results
3.1. Umbilical cord and placenta method validation results
For EtG and EtS in umbilical cord, the method calibration was achieved via a
linear, non-forced model. EtG was determined to behave superiorly with an inversely
weighted model, while an inverse square model was best suited for EtS. In umbilical cord
the LOQ and LOD for EtG and EtS were both 5 ng/g, and the linear range was 5-500
ng/g. Linearity for the method met the criteria for acceptability by demonstrating a
coefficient of determination greater than 0.99 and maintaining residuals within a 20%
range for both EtG and EtS. No endogenous or exogenous interferences were detected for
the method.
For EtG, the inter-day imprecision was between 4.65-11.18% and the intra-day
imprecision was between 1.63-11.81%, based on a 5-day analysis of low and high QC
samples and LOQ samples. Inter-day accuracy was between 90-95.78% with a bias
measurement between -10 -4.22%, assessed via the same QC and LOQ samples, and
intra-day accuracy was between 82.67- 102% with a bias measurement between -17.332%.
For EtS, the inter-day imprecision was between 1.85-6.81% and the intra-day
imprecision was between 1.09-9.08%, based on a 5-day analysis of low and high QC
samples and LOQ samples. Inter-day accuracy was between 87.2-100% with a bias
measurement between -12.8-0%, assessed via the same QC and LOQ samples, and intraday accuracy was between 83.61- 102.89% with a bias measurement between -16.392.89%. These results are presented in Tables 4 and 5.
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There was no evidence of carryover detected for either EtG or EtS, as calculated
results for the reinjected blank were below the LOD/LOQ for the method. Auto-sampler
stability results demonstrate there was no indication of analyte instability for either EtG
or EtS after 24 hours and 48 hours in the auto-sampler at 10˚C. Results after 24 and 48
hours demonstrate a percent difference below 6% and accuracy within ± 13% of the
target concentration.
ME, EE and PE were also evaluated at LQC and HQC concentrations for EtG and
EtS, as well as the respective deuterated analogs. ME for LQC samples demonstrated a
75.08% ion suppression for EtG with a CV of 10.12% for the after-fortification sample
set (n=6), and a 71.54% ion suppression for EtG-d5 with a CV of 3.91 for the afterfortification sample set (n=6). EtS had a 19.67% ion suppression with a CV of 33.75%
for the after-fortification sample set (n=6) and a 28.82% ion suppression for EtS-d5 with a
CV of 16.45% for the after-fortification sample set (n=6). ME for the HQC samples
demonstrated a 58.77% ion suppression for EtG with a CV of 6% for the afterfortification sample set (n=6), and a 59.05% ion suppression for EtG-d5 with a CV of
2.46% for the after-fortification sample set (n=6). EtS had a 9.84% ion suppression with a
CV of 8.21% for the after-fortification sample set (n=6), and a 23.08% ion suppression
for EtS-d5 with a CV of 4.31% for the after-fortification sample set (n=6). For EtG and
EtS respectively, at the LQC concentration, EE was 74.21% and 83.96%, and PE was
18.49% and 67.44%, and at the HQC concentration, EE was 68.99% and 79.28%, and PE
was 28.44% and 71.48%. For EtG-d5 and EtS-d5 respectively, at the LQC concentration,
EE was 75.71% and 85.89%, and PE was 21.57% and 61.14%, and at the HQC
concentration, EE was 71.95% and 81.1%, and PE was 29.47% and 62.38%.
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Table 4: Accuracy and imprecision results for EtG in umbilical cord.

Imprecision
(%)

Intra-day
(n=3)
Inter-day
(n=5)

Accuracy
(%)

Intra-day
(n=3)
Inter-day
(n=5)

Conc
(ng/g)
5
15
300
5
15
300
5
15
300
5
15
300

Day 1

Day 2

Day 3

Day 4

Day 5

9.8
2.13
3.83

2.33
9.39
6.1

10.87
10.14
1.63

10
7.83
3.94

11.81
2.13
1.9

102
94
89.27

11.18
7.91
4.65
86
101.33
88.67 94.44
90.52 88.49
95.78
90
90.71

100
90.22
96.36

88
82.67
88.93

Day 4

Day 5

1.17
3.34
1.59

2.34
1.09
1.98

98.67
94.22
88.98

98.67
93.11
87.42

Table 5: Accuracy and imprecision results for EtS in umbilical cord.

Imprecision
(%)

Accuracy
(%)

Intra-day
(n=3)
Inter-day
(n=5)
Intra-day
(n=3)
Inter-day
(n=5)

Conc
(ng/g)
5
15
300
5
15
300
5
15
300
5
15
300

Day 1

Day 2

2.28
6.4
7.19

1.15
8.2
5.9

Day 3

1.15
9.08
2.95
1.85
6.81
4.9
101.33 100.67 100.67
99.33 94.22 102.89
90.81 83.61 85.18
100
96.75
87.2

For EtG and EtS in placenta, the method calibration was achieved via a nonforced model. EtG was determined to behave superiorly with a linear, inversely squared
weighted model, while a non-weighted quadratic model was best suited for EtS. In
placenta the LOQ and LOD for EtG and EtS were both 10 ng/g, and the linear range was
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10-500 ng/g. Linearity for the method met the criteria for acceptability by demonstrating
a coefficient of determination greater than 0.99 and maintaining residuals within a 20%
range for both EtG and EtS. No endogenous or exogenous interferences were detected for
the method.
For EtG, the inter-day imprecision was between 5.1 - 9.68% and the intra-day
imprecision was between 0.98 - 11.3%, based on a 5-day analysis of low and high QC
samples and 3-day analysis of LOQ samples. Inter-day accuracy was between 91.76 –
103.2% with a bias measurement between -8.24 – 3.20%, assessed via the same QC and
LOQ samples, and intra-day accuracy was between 88.28 – 112.44% with a bias
measurement between -11.72 – 12.44%.
For EtS, the inter-day imprecision was between 5.54 – 7.87% and the intra-day
imprecision was between 0.58 – 6.97%, based on a 5-day analysis of low and high QC
samples and 3-day analysis of LOQ samples. Inter-day accuracy was between 88.78 –
100.58% with a bias measurement between -11.22 – 0.58%, assessed via the same QC
and LOQ samples, and intra-day accuracy was between 83.08 – 108.67% with a bias
measurement between -16.92 – 8.67%. These results are summarized in Tables 6 and 7.
Accuracy and imprecision data for days 1 and 2 for EtG and day 1 for EtS are not
available due to sample volume of the extract. After evaporation and reconstitution of the
sample eluate, samples were centrifuged and a portion was transferred to the analysis vial
or filter vial. Due to the limited sample size, multiple injections of the same sample were
not possible to study the accuracy and imprecision on that day.
There was no evidence of carryover detected for either EtG or EtS, as calculated
results for the reinjected blank were below the LOD/LOQ for the method. Auto-sampler
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stability results demonstrated there was no indication of analyte instability for either EtG
or EtS after 48 hours in the auto-sampler at 10˚C. Results after 48 hours demonstrate a
percent difference below 7% and accuracy within ±7%.
ME, EE and PE were also evaluated at low QC and high QC concentrations for
EtG and EtS, as well as the respective deuterated analogs. ME for LQC samples
demonstrated a 67.73% ion suppression for EtG with a CV of 10.57% (n=6) for the afterfortification sample set, and a 65.65% ion suppression for EtG-d5 with a CV of 6.34% for
the after-fortification sample set (n=6). EtS has a 5.32% ion suppression for EtS with a
CV of 15.97% (n=6) for the after-fortification sample set, and a 0.57% ion suppression
for EtS-d5 with a CV of 8.67% for the after-fortification sample set (n=6). ME for the
HQC samples demonstrated a 69.92% ion suppression for EtG with a CV of 7.15% for
the after-fortification sample set (n=6), and a 67.1% ion suppression for EtG-d5 with a
CV of 7.1% for the after-fortification sample set (n=6). EtS had a 15.23% ion suppression
with a CV of 7.81% for the after-fortification sample set (n=6), and an 8.8% ion
suppression for EtS-d5 with a CV of 5% for the after-fortification sample set (n=6). For
EtG and EtS respectively at the LQC concentration, the EE of the process was 81.33%
and 92.69%, and the PE was 26.25% and 97.62%, and at the HQC the EE of the process
was 75% and 83.43%, and the overall PE was 22.56% and 70.73%. For EtG-d5 and EtSd5 respectively at the LQC concentration, the EE of the process was 77.56% and 86.82%,
and the PE was 26.64% and 87.31%, and at the HQC the EE of the process was 76.21%
and 83.71%, and the overall PE was 25.08% and 76.34%.
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Table 6: Accuracy and imprecision results for EtG in placenta.

Imprecision
(%)

Accuracy
(%)

Intra-day
(n=3)
Inter-day
(n=5)
Intra-day
(n=3)
Inter-day
(n=5)

Conc
(ng/g)
5
15
300
5 (n=3)
15
300
5
15
300
5 (n=3)
15
300

Day 1

Day 2

----6.74
3.65

----11.3
3.53

----112.44
97.39

Day 3

9.66
7.82
4.22
6.18
9.68
5.11
----102
106.67 99.56
88.28
90.1
102
103.2
91.76

Day 4

Day 5

7.66
9.37
4.62

0.98
8.27
4.53

102
102.89
93.49

102
94.44
89.53

Day 4

Day 5

Table 7: Accuracy and imprecision results for EtS in placenta.

Imprecision
(%)

Accuracy
(%)

Intra-day
(n=3)
Inter-day
(n=5)
Intra-day
(n=3)
Inter-day
(n=5)

Conc
(ng/g)
5
15
300
5 (n=4)
15
300
5
15
300
5 (n=4)
15
300

Day 1

Day 2

----6.97
3.2

2.96
1.15
4.44

----88.89
89.53

Day 3

1.63
0.58
0.58
2.28
5.5
6.46
3.91
3.25
2.61
5.76
7.87
5.54
108.67 93.67 100.33 99.67
100
102.89 100.89 108.67
85.76 94.44
91.1
83.08
100.58
100.27
88.78

3.2. Authentic specimens’ results
3.2.1. EtG and EtS in Umbilical Cord
EtG and/or EtS were detected in 25 umbilical cord samples out of 59. The
average±SD EtG concentration detected was 144.91±204.63 ng/g (n=8) and the
average±SD EtS concentration was 14.72±11.41 ng/g (n=22). Raw data indicates EtG has
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a 13.6% detection rate and EtS has a 37.3% detection rate in umbilical cord. Both EtG
and EtS were detected in 5 samples, with concentration ranges of 4.8-528.5 ng/g and 5.239 ng/g, respectively. EtG alone was detected in 3 additional samples analyzed (4.4-19.4
ng/g) and EtS alone was detected in 17 additional samples (4.3-38.8 ng/g).

Figure 1: MRM chromatogram of the authentic sample 2013_V31 positive for EtG
at 46.4 ng/g and EtS at 22.3 ng/g. In black the quantifier transition, in pink the
qualifier transition.
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To investigate the distribution of EtG and EtS in umbilical cord, 5 authentic
umbilical cord samples, where both EtG and EtS were present at a concentration
significantly above the LOQ, were investigated. The range of EtG in the 5 samples the
first time they were analyzed was 4.8-528.5 ng/g, and for EtS was 5.2-39 ng/g. The 5
samples of interest were segmented into 3 parts, the top, middle and the end portions of
the cord sample. The range of EtG after segmental analysis was 4.9-544.8 ng/g and for
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EtS was 5-38.9 ng/g. Both EtG and EtS showed a homogenous distribution across the
umbilical cord tissue with a CV < 10.3% (n=5).
3.2.2. EtG and EtS in Placenta
EtG and/or EtS were detected in 8 placenta samples out of 59. The average±SD
EtG concentration detected was 129.6±120 ng/g (n=5), while the average EtS
concentration was 15.18±5.51 ng/g (n=6). Raw detection rates in placenta were almost
the same for both EtG and EtS, at 8.5% and 10.2% respectively. EtG and EtS were both
detected in 3 placenta samples with concentration ranges of 76.9 – 266.5 ng/g and 13.2 –
24.3 ng/g, respectively. An additional 2 samples contained EtG only (26.5 – 26.7 ng/g),
and an additional 3 samples contained EtS alone (11 – 12 ng/g).

Figure 2: MRM chromatogram of the authentic sample S101 positive for EtG at
251.4 ng/g and EtS at 19.6 ng/g. In black the quantifier transition, in pink the
qualifier transition.
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3.2.3. Comparison of EtG and EtS in umbilical cord, placenta and meconium
As compared to the 59 meconium samples positive for EtG, 25 umbilical cord
samples tested positive for EtG and/or EtS. These paired umbilical cord samples
demonstrated a higher frequency of detection for EtS (n=22) than for EtG (n=8). Whereas
EtG was detected above 5 ng/g in 59 meconium, 34 paired umbilical cord samples had no
detectable EtG or EtS levels above the same cutoff. In the case of placenta, 8 samples
tested positive for EtG and/or EtS above 10 ng/g. The frequency of detection of EtG
(n=5) and EtS (n=6) in placenta was similar. The average±SD concentration for EtG in
meconium was 611.86±2761.2 ng/g, while the average concentration in cord was
144.91±204.63 ng/g and in placenta 129.6±120 ng/g, which were within a similar range
to one another as opposed to meconium. EtS in umbilical cord and placenta were also in a
similar range, 14.72±11.41 ng/g and 15.18±5.51 ng/g respectively.
In paired meconium samples (EtG > 5 ng/g), there was a 13.6% agreement in EtG
detection in umbilical cord (ncord=8, nmeconium=59). The meconium concentrations in the
paired positive samples were 31.5-19,680 ng/g (n=8). Percent agreement was determined
by comparing the amount of positive cord samples against the paired positive meconium
samples to determine which pairs yielded two positive results in the respective matrices.
In pairs where EtG was detected in meconium (EtG > 5 ng/g), there was a 37.3%
agreement in EtS detection (ncord=22, nmeconium=59), and the meconium concentrations in
the paired positive samples were 5.62-19,680 ng/g (n=22). Finally, in pairs were EtG was
detected in meconium (EtG > 5 ng/g), there was an 8.5% agreement in both EtG and EtS
detection in umbilical cord (ncord=5, nmeconium=59), and meconium concentrations in the
paired positive samples were 31.5-19,680 ng/g (n=5).
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Applying different EtG meconium cutoffs from various sources to detect in-utero
ethanol exposure, we determined the percentage of umbilical cord samples that tested
positive for EtG and/or EtS above the LOQ. The meconium EtG cutoffs employed were:
30 ng/g cutoff (Himes et al., 2015); 120 ng/g cutoff (Goecke et al., 2014); 274 ng/g cutoff
(Bakdash et al., 2010); 333 ng/g cutoff (Morini et al., 2010b); and 444 ng/g cutoff
(Pichini et al., 2012). These results are summarized in Table 8.
Table 8: Various rates of detection in umbilical cord based on meconium EtG
cutoffs.
EtG
meconium
cutoff

5 ng/g
30 ng/g
120 ng/g
274 ng/g
333 ng/g
444 ng/g

N paired
samples

59
44
18
12
10
8

% Agreement with umbilical cord samples (# of
samples)
EtG
positive

EtS
positive

EtG and EtS
positive

EtG or EtS
positive

13.6% (8)
18.2% (8)
22.2% (4)
33.3% (4)
40% (4)
50% (4)

37.3% (22)
40.9% (18)
44.4% (8)
41.7% (5)
50% (5)
62.5% (5)

8.5% (5)
11.4% (5)
16.7% (3)
25% (3)
30% (3)
37.5% (3)

42.4% (25)
47.7% (21)
50% (9)
50% (6)
60% (6)
75% (6)

In paired meconium samples (EtG>5 ng/g), there was an 8.5% agreement in EtG
detection in placenta (nplacenta=5, nmeconium=59). The meconium concentrations in the
paired positive samples were 68.82-19,680 ng/g (n=5). In pairs where EtG was detected
in meconium (EtG>5ng/g), there was a 10.2% agreement in EtS detection in placenta
(nplacenta=6, nmeconium=59), and the meconium concentrations in the paired positive samples
were 23.8-19,680 ng/g (n=6). Finally, in pairs were EtG was detected in meconium, there
was a 5.1% agreement in both EtG and EtS detection in placenta (nplacenta=3,
nmeconium=59), and meconium concentrations in the paired positive samples were 68.82-
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19,680 ng/g (n=3). The remainder of the data utilizing various meconium EtG cutoffs is
presented in Table 9.
Table 9: Various rates of detection in placenta based on meconium EtG cutoffs.
EtG
meconium
cutoff

5 ng/g
30 ng/g
120 ng/g
274 ng/g
333 ng/g
444 ng/g

N paired
samples

59
44
18
12
10
8

% Agreement with placenta samples (# of samples)

EtG
positive

EtS
positive

EtG and EtS
positive

EtG or EtS
positive

8.5% (5)
11.4% (5)
22.2% (4)
33.3% (4)
40% (4)
50% (4)

10.2% (6)
11.4% (5)
11.1% (2)
16.7% (2)
20% (2)
25% (2)

5.1% (3)
6.8% (3)
11.1% (2)
16.7% (2)
20% (2)
25% (2)

13.6% (8)
15.9% (7)
22.2% (4)
33.3% (4)
40% (4)
50% (4)

3.2.4 Comparison of EtG and EtS in biological samples and self-reports
Among the 59 cases analyzed, one mother reported daily alcohol use during the
pregnancy, 9 reported alcohol consumption on the weekends, 18 sporadic use (sometimes
during pregnancy), 21 no use, and 10 did not answered. In the case of the daily user, the
meconium EtG was the highest (19,680 ng/g) and EtG and EtS were detected in umbilical
cord (397.5 and 32.1 ng/g respectively) and in placenta (251.4 ng/g and 19.6 ng/g).
In the cases where alcohol use was reported on the weekends (n=9), meconium
EtG concentrations ranged from 11.6 to 490.8 ng/g. EtG and/or EtS were detected in 5
umbilical cord samples (EtG, 145.1 ng/g, n=1; EtS, 5.4-38.8 ng/g, n=5), and in 2 placenta
samples (EtG, 76.9 ng/g, n=1; EtS, 11-13.2 ng/g, n=2). If sporadic alcohol use was
declared (n=18), meconium EtG concentrations ranged from 5.2 to 370.3 ng/g. EtG
and/or EtS were detected in 7 umbilical cord samples (EtG, 4.8-19.4 ng/g, n=2; EtS, 4.5-
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26.3 ng/g, n=6), and in 2 placenta samples (EtG, 26.5 ng/g, n=1; EtS, 11 ng/g, n=1).
Although 21 mothers declared no alcohol use during pregnancy, EtG was detected
in meconium at concentrations from 7.9 to 792.6 ng/g. Ten umbilical cord samples were
positive for EtG and/or EtS (EtG, 13.2-46.4 ng/g, n=2; EtS, 4.3-22.3 ng/g, n=9), and 2
placenta samples (EtG, 26.7 ng/g, n=1; EtS, 12 ng/g, n=1). In the 10 cases where the
mothers did not answer, EtG was detected in meconium from 19.7 to 8,549 ng/g. Two
cases were positive for EtG and/or EtS in umbilical cord (EtG, 4.4-528.5 ng/g, n=2; EtS,
39 ng/g, n=1), and one placenta was positive for EtG (266.5 ng/g) and EtS (24.3 ng/g).

4. Discussion
We developed and validated two sensitive and specific analytical methods for the
determination of EtG and EtS in both umbilical cord and placental tissues. From a single
sample aliquot of 0.1 g, the samples were homogenized in a tissue blender, extracted by
weak anion exchange solid phase extraction and analyzed by LC-MSMS. We were able
to achieve an LOD/LOQ of 5 ng/g and a linear range of 5-500 ng/g for both EtG and EtS
in cord tissue and an LOD/LOQ of 10 ng/g and linear range of 10-500 ng/g for both
analytes in placenta. Most methods have been developed for use with meconium and
have looked at both EtG and EtS with success (Himes et al., 2014; Morini et al., 2010a;
Morini et al., 2010b); however, the literature in umbilical cord and placenta is scarce.
Only one analytical paper has been published for the determination of EtG in umbilical
cord (Jones et al., 2012) and two for the determination of EtG and EtS in placenta
(Morini et al., 2011; Swortwood et al., 2018). All of these publications employed LCMSMS as the analytical technique. Jones et al. reported a lower EtG LOQ of 3 ng/g than
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in our method (5 ng/g), but that method required 1 g of umbilical cord (x10 the amount
required in our method) and EtS was not included. Umbilical cord samples were
homogenized with a bullet blender and extracted by strong anion exchange solid phase
extraction (Jones et al., 2012). Morini et al. (2011) developed a method for the
determination of EtG and EtS in 0.5 g of placenta achieving a LOQ of 5 ng/g. EtG and
EtS were extracted by briefly vortexing the tissue in acetonitrile, and after 1:10 dilution
in water, the samples were injected in the LC-MSMS instrument. Swortwood et al.
(2018) homogenized 0.25 g of placenta in methanol in a bead mill, and half of the aliquot
was employed to extract EtG and EtS by strong anion exchange solid phase extraction
following a procedure previously described by these authors for meconium (Himes et al.,
2014). The LOQ was 20 ng/g for EtG and 5 ng/g for EtS.
The present developed and validated methods were applied to 59 authentic
umbilical cord and placenta samples, from newborns whose meconium tested positive for
EtG (EtG > 5 ng/g). EtG was detected in 8 umbilical cord samples with concentration
ranges of 4.4-528.5 ng/g. Jones et al. (2012) applied their method to 308 de-identified
umbilical cord samples that were received by their laboratory for routine toxicological
analysis. They detected EtG in 12 samples with a concentration range of 4-666 ng/g,
similar to the concentrations determined in our study. We observed that EtS was detected
in a total of 22 cases (4.3-39 ng/g), 5 cases along with EtG and 17 cases alone. Morini et
al. (2010a, b) noted that the presence of EtS without EtG may indicate a false positive in
meconium, as it is advisable to have both markers to confirm ethanol consumption.
However, in this study the EtS only cases in umbilical cord were positive for EtG in
meconium (5.63-792.6 ng/g), suggesting ethanol exposure during pregnancy. The
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observed differences between EtG and EtS detection in umbilical cord samples could be
explained due their different stability in biological samples. EtG is prone to bacterial
decomposition, while EtS is not (Baranowski et al., 2008). Currently, there are no data
available about the stability of EtG and EtS in this type of biological samples, therefore
further research is necessary.
Regarding placenta, EtG was detected in 5 samples and EtS in 6 out of 59 cases,
with concentration ranges of 26.5 – 266.5 ng/g and 11 – 24.3 ng/g, respectively. EtG and
EtS were detected together in 3 cases, EtG only in 2 cases and EtS only in 3 cases. Morini
et al. (2011) analyzed EtG and EtS in 35 placenta samples from fetuses voluntarily
terminated at 12 weeks of gestation. Four samples were positive for both EtG and EtS
and only 2 samples were positive for only EtS. The concentration ranges for EtG and EtS
respectively were 122-1306.49 ng/g and 9.59-175.32 ng/g. Swortwood et al. (2018)
applied their method for the determination of EtG and EtS in placenta of 48 authentic
samples from pregnancies voluntarily terminated at 8-20 weeks. Ten samples were
positive for both EtG and EtS, and an additional 6 samples were positive for EtG only
and 7 for EtS only. The concentration range for EtG and EtS respectively was 34.3-1168
ng/g and 6.9-214 ng/g. Both studies reported higher maximum concentrations for EtG
and EtS in placenta from terminated pregnancies by 8-20 weeks, than in our study from
term placentas. Different alcohol consumption pattern among the mothers, or tissue
differences due to the week of gestation, may explain these differences.
Currently, there are no data available comparing EtG and EtS in umbilical cord
and other tissues. Regarding placenta, comparisons of placenta and other tissues, such as
fetal and liver tissues, have been done previously (Morini et al., 2011; Swortwood et al.,
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2018). Morini et al. (2011) analyzed 35 fetal tissue-placenta pairs at gestational week 12.
Four cases tested positive for EtG and/or EtS in fetal tissue and placenta, and 2 placenta
samples tested positive for EtS but negative in fetal tissue. Swortwood et al. (2018)
compared 47 paired placenta and fetal liver samples at gestational week 8-20. Twentyone were negative in both samples; 11 cases showed EtG and EtS in liver and placenta,
and in 15 cases EtG and/or EtS were detected in only one matrix (12 only in placenta, and
3 only in liver).
In the present study, we compared for the first time EtG and EtS detection in
matched umbilical cord, placenta and meconium samples. We observed higher
concentrations of EtG in meconium compared to umbilical cord and placenta, while
umbilical cord and placenta showed similar range of concentration for EtG and EtS. Out
of 59 cases with positive meconium results (EtG > 5 ng/g), EtG and/or EtS were detected
in 25 umbilical cord and in 8 placenta samples. Different distribution/accumulation of
drugs and metabolites have been reported in umbilical cord, placenta and meconium, due
to the tissues different composition, formation and dynamics, and chemical properties of
the analytes (Concheiro & Huestis, 2018). Several studies showed a good agreement
between meconium and umbilical cord for cocaine, amphetamines, opioids,
benzodiazepines, cannabis and tobacco detection, but in general meconium had better
sensitivity (Concheiro et al., 2017; Labardee et al., 2017; Colby et al., 2017; Kim et al.,
2017; Marin et al., 2011). Comparisons with placenta are scarce. Previous studies from
our group showed similar concentrations in placenta and umbilical cord for cocaine,
opioids and methadone (Concheiro et al., 2010; Concheiro et al., 2017). Regarding tissue
distribution, we investigated the distribution of EtG and EtS in the umbilical cord. As
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already reported for other drugs of abuse (de Castro et al., 2011), we observed a
homogeneous distribution of EtG and EtS throughout the umbilical cord tissue.
We compared the umbilical cord and placenta results with different cut-offs of
EtG in meconium, which has been suggested in the literature (30, 120, 274, 333 and 444
ng/g). The 30 ng/g cutoff was determined by Himes et al. (2015), comparing the extent of
agreement between positive meconium samples and maternal self-reports of ethanol
consumption (Himes et al., 2015). Goecke et al. (2014) also determined their meconium
EtG cutoff at 120 ng/g based on analysis of the statistically significant p-value when
studying their results against self-reports. Bakdash et al. (2010) utilized FAEE
concentrations >500 ng/g in conjunction with EtG concentrations to establish a
meconium EtG cutoff at 274 ng/g. Morini et al. (2010b) utilized both EtG and EtS, as a
confirmation, in order to determine a meconium cutoff. They did so by establishing the
increase in positive samples as the cutoff value for the two target analytes was increased
and then cross comparing those levels with FAEEs levels. Morini et al. (2010b)
determined that when the cutoff for EtG was increased to 333 ng/g, all of the samples that
tested positive were also positive for EtS at 1.5 ng/g or higher. Finally, Pichini et al.
(2012) established the EtG cutoff at 444 ng/g by comparing meconium samples from
teetotalers against meconium samples from births where mothers admitted to drink
ethanol during pregnancy and meconium FAEEs were > 2 nmol/g. We found agreements
up to 75% with umbilical cord and 50% with placenta, when the highest cutoff (Pichini et
al., 2012) was applied.
5. Conclusion
We have successfully developed and validated two analytical methods for the
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detection of maternal alcohol consumption and fetal alcohol exposure via EtG and EtS in
umbilical cord and placenta. Our method proved to be sensitive and specific, needing
only 0.1 g tissue to achieve 5 and 10 ng/g LOQ in umbilical cord and placenta,
respectively.
Umbilical cord and placenta showed to be alternative matrices to meconium to
detect ethanol in-utero exposure, showing umbilical cord a better agreement with
meconium than placenta. We demonstrated a homogenous distribution of EtG and EtS
throughout the umbilical cord tissue. Further research is guaranteed to investigate in more
depth the window of detection of umbilical cord and placenta for EtG and EtS, and the
amount of ethanol exposure that yields positive results in these biological samples.
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